JPRN-UMIN000011562
Recruiting
未知
Efficacy and safety of everolimus (Certican) plus once-daily prolonged-release tacrolimus (Graceptor) combination therapy in living donor kidney transplantation: Open-label, multicenter, randomized controlled trial. - Efficacy and safety of everolimus plus once-daily prolonged-release tacrolimus combination therapy in living donor kidney transplantation: Open-label, multicenter, randomized controlled trial.
Tokyo Women's Medical University, Dep. Urology0 sites120 target enrollmentOctober 1, 2013
ConditionsKidney transplantation
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Kidney transplantation
- Sponsor
- Tokyo Women's Medical University, Dep. Urology
- Enrollment
- 120
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Inability or un willingness to sign a consent form. 2\. Subject under 20 years old. 3\.ABO blood incompatible kidney transplantation 4\.Unable to outpatient treatment in study period 5\.Pregnancy or possible to pregnant 6\.Serious digestive disease 7\.Active infectious disease 8\. Cancer 9\. Hypersensibility to sirolimus or everolimus 10\. Investigator considered inappropriate as a subject of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study.• Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung• Well to moderately differentiated neuroendocrine carcinoma (NET G1/G2) that switched to G3 (confirmed by histology)• Neuroendocrine tumor G3 (NET G3)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-004550-28-DEAIO-Studien-gGmbH
Completed
Phase 4
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant RecipientsChronic Renal FailureNCT00965094Novartis Pharmaceuticals36
Active, not recruiting
Not Applicable
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-CZovartis Pharma AG490
Active, not recruiting
Not Applicable
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIEUCTR2004-002267-24-HUovartis Pharma AG384
Active, not recruiting
Not Applicable
Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN) - ASCERTAIRenal transplantationMedDRA version: M15Classification code 10023438EUCTR2004-002267-24-ESovartis Pharma AG483